MOST RECENT
Started by a group of families to support a single researcher, this funder aims to advance basic science and drive better treatments and cures. It now provides millions in annual grants and has plans to expand further.
Before being forced out of the company, Adam and Rebekah Neumann signaled some big philanthropic aspirations. They’re still very wealthy; did they continue giving?
Cancer Grand Challenges has announced $125 million across five new grants to take on key questions in cancer research and to better understand causes of poorer health outcomes for certain patient populations.
The neurodegenerative disease gets less funder attention than other more common conditions, which is why a set of new $1 million research grants from the Hereditary Disease Foundation could really move the needle.
Aligning Science Across Parkinson's, established by the Google cofounder, wants to diversify genetic research into the neurodegenerative disease. Its latest big grant will expand the geographic scope of a key international study.
The ACS is the largest nongovernment, nonprofit funder of cancer research in the U.S. We spoke with the head of BrightEdge, its venture capital team, which uses a for-profit model to advance the mission.
A top priority for cancer research funders is ensuring that patients receive equitable and timely access to treatment and care. We check in with a leading advocate and grantmaker to see how it’s approaching this work.
For World AIDS Day, guest authors Athena Cross, Carl Baloney and Jesse Milan Jr. call attention to diminishing HIV-related philanthropic support, despite prevailing racial equity gaps in diagnoses and treatment.
The late Microsoft co-founder’s Paul G. Allen Frontiers Group has launched its newest Discovery Center. Its goal: exploring how the human nervous system and immune system interact to shape health and disease.
Tackling demographic disparities in outcomes and care has been a big priority for cancer funders lately. Susan G. Komen, a major backer of breast cancer research, care and advocacy, is no exception.
Mike and Sofia Segal came to the U.S. in 1978 from Ukraine with $120 and built a fortune in the electric power industry. Now, they're rolling out a set of big donations, starting with a $17 million gift to fight a rare blood cancer.
Philanthropy for veterans often stems from personal or family experience, making a decline in the percentage of Americans who’ve served a cause for concern. But these veterans-focused funders bucked that trend in 2023.
The Engelstad Foundation supported Touro University Nevada's lone biomedical lab when few other funders would. A recent discovery there could lead to new treatments for HIV, and even cancer, Alzheimer’s and more.
Philanthropy makes up only a small fraction of spending on research and support for people with HIV, still a major threat around the world. In the push for a vaccine, Gates and Gilead are leading the pack.
ALS remains a devastating disease, but research is advancing, thanks in large part to the efforts of those impacted. Eric and Amanda Stevens have turned to the athlete and first responder communities to raise awareness and funds.
Among non-communicable diseases, diabetes has a particularly low profile as a global health concern. The Helmsley Charitable Trust has made it a central focus, including two recent commitments to the WHO.
To build up collaborative research infrastructure, a landmark $100 million gift from businessman Gene Lay will launch a new institute spanning Brigham and Women's Hospital, Mass General and Harvard Medical School.
A study commissioned by the Disability & Philanthropy Forum is a must-read for funders aiming to drive social justice for disabled people and address complex and overlapping issues of racial, gender and other inequities.
We can't have too many ways to fight cancer. Here’s who’s backing a nonprofit startup that’s using AI to repurpose generic drugs that could mean the difference between life and death for patients — and solvency or bankruptcy.
Effective altruism has had a rough year, but remains a major force within philanthropy. We take a closer look at two of this EA-driven outfit’s programs: farm animal welfare and biosecurity and pandemic preparedness.
The $78 million gift from a foundation built by an heir to the du Pont fortune will fuel research and clinical care for children with cancer, sickle cell disease and other life-threatening blood disorders.
The Gates Foundation, Novo Nordisk Foundation and Open Philanthropy are collaborating under a partnership called Pandemic Antiviral Discovery, funding research to develop treatments that may be needed for future pandemics.
Stanley and Fiona Druckenmiller have a $1.9 billion foundation and a reported fortune of $10 billion. Here’s a closer look at how the couple makes big bets for economic mobility, the environment and health.
In this candid conversation, the storied investor and mega-donor discusses what he and his wife Fiona look for in grantees, how much they plan to give away, why they won’t sign the Giving Pledge, and more.
With a $100 million commitment, the Howard Hughes Medical Institute is the latest funder backing research to prepare for pathogens with the potential to threaten human health, or even trigger new pandemics.
Paul and Diane Manning, longtime supporters of diabetes research at the University of Virginia, recently committed $100 million to build an advanced biotech research institute there. Here’s a rundown on the gift and the donors.
Sergey Brin’s foundation has nearly $5 billion in assets and a portfolio spanning Parkinson’s disease, science and activism. It’s not known for transparency, but we do know a fair amount about what it supports and why.
As part of IP’s State of American Philanthropy project, we recently published an in-depth paper on trends in cancer research funding. Author Mike Scutari overviews what we learned and offers clues on what to expect going forward.
The Chicago-based Muscular Dystrophy Association is a leading funder in the field of neuromuscular diseases. We check in with Chief Research Officer Dr. Sharon Hesterlee to discuss current challenges and priorities.
The FDA recently approved a new drug to treat ALS. Here’s how the ALS Association, equipped with funding from 2014’s viral Ice Bucket Challenge, contributed to that outcome — and what it’s looking to do next.